Indoco Remedies share news, announcements and annual reports
NSE: INDOCOBSE: 532612Pharmaceuticals & BiotechnologySmall Cap
Indoco Remedies Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 2005
Last close ₹208.30down ₹1.20 (0.57%)BSE ₹208.35
Share price at the NSE close on 30 Oct 2026. Previous close ₹209.50.
30 Oct: open ₹208.65, high ₹210.00, low ₹205.10
52-week range of traded prices to 30 Oct 2026
₹162.19Low, 30 Mar 2026₹288.00High, 6 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,923 Cr1,173rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 60.20
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹132 crore of one-off items, the largest of them in the quarter to Jun 2026.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.88
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.10%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 3.2%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹132 crore of one-off items, the largest of them in the quarter to Jun 2026.
- −10.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 1.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.96
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 64,72755.0% delivered
Indoco Remedies board meetings
103 filed, newest first. Page 3 of 3.
Oct 2007
10 Oct · Board meeting
Inter-alia, for considering the audited financial results for the fourth quarter and financial year ended on June 30, 2007, and recommendation of dividend, if any, for the financial year 2006-2007.
Apr 2007
17 Apr · Board meeting
Inter-alia, to take on record the un-audited Quarterly results for the period January 01, 2007 to March 31, 2007 and also un-audited results for the period July 01, 2006 to March 31, 2007.
Jan 2007
16 Jan · Board meeting
Inter-alia, for the follow:- (i) To take on record the un-audited Quarterly results for the second quarter period October 01, 2006 to December 31, 2006. (ii) To consider the amalgamation of M/s. La Nova Chem (India) Pvt. Ltd., a 100% subsidiary of the Company, with the Company. (iii) To consider the acquisition of the pharmaceutical business of M/s. SPA Pharmaceuticals Pvt. Ltd, Mumbai, by a legal demerger process.